Research Papers:
TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1384 views | HTML 2367 views | ?
Abstract
Kathy L. McGraw1,*, Thomas Cluzeau1,2,3,4,5,*, David A. Sallman1, Ashley A. Basiorka6, Brittany A. Irvine1, Ling Zhang7, P.K. Epling-Burnette8, Dana E. Rollison9, Mar Mallo10, Lubomir Sokol1, Francesc Solé10, Jaroslaw Maciejewski11, Alan F. List1
1Department of Malignant Hematology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA
2Hematology Department, CHU of Nice, Nice, France
3University Nice Sophia Antipolis, Faculty of Medicine, Nice, France
4Mediterranean Center of Molecular Medicine, INSERM U1065, Nice, France
5French Group of Myelodysplasia, France
6Moffitt Cancer Center and Research Institute and The Cancer Biology Ph.D. Program, University of South Florida, Tampa, FL, USA
7Department of Pathology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA
8Department of Immunology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA
9Department of Cancer Epidemiology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA
10Institut de Recerca Contra la Leucèmia Josep Carreras (IJC) Badalona, Barcelona, Spain
11Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA
*These authors have contributed equally to this work
Correspondence to:
Kathy L. McGraw, e-mail: [email protected]
Keywords: TP53, MDM2, myelodysplastic syndromes, single nucleotide polymorphisms, survival
Received: June 02, 2015 Accepted: September 14, 2015 Published: September 25, 2015
ABSTRACT
P53 is a key regulator of many cellular processes and is negatively regulated by the human homolog of murine double minute-2 (MDM2) E3 ubiquitin ligase. Single nucleotide polymorphisms (SNPs) of either gene alone, and in combination, are linked to cancer susceptibility, disease progression, and therapy response. We analyzed the interaction of TP53 R72P and MDM2 SNP309 SNPs in relationship to outcome in patients with myelodysplastic syndromes (MDS). Sanger sequencing was performed on DNA isolated from 208 MDS cases. Utilizing a novel functional SNP scoring system ranging from +2 to −2 based on predicted p53 activity, we found statistically significant differences in overall survival (OS) (p = 0.02) and progression-free survival (PFS) (p = 0.02) in non-del(5q) MDS patients with low functional scores. In univariate analysis, only IPSS and the functional SNP score predicted OS and PFS in non-del(5q) patients. In multivariate analysis, the functional SNP score was independent of IPSS for OS and PFS. These data underscore the importance of TP53 R72P and MDM2 SNP309 SNPs in MDS, and provide a novel scoring system independent of IPSS that is predictive for disease outcome.
![Creative Commons License](/images/80x15.png)
PII: 5255